Acute Lung Injury — Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Citation(s)
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure